Stock Ratings / Health Care / XNCR / options

PVLA (46) IMNM (38) MRVI (36) VERA (35) ⌘ Pro Terminal →

Xencor Inc. (XNCR) Options Positioning, Max Pain & Unusual Sweeps

$29.21 -2.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Xencor Inc. (XNCR) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $2.17B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XNCR)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (XNCR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for XNCR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XNCR)

✓Walkthrough of XNCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XNCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +144.84%▲ ASCENDING CHANNEL

2026-10-30O $29.09H $30.05L $28.61C $29.21VOL 1.29M

RES: $33.88SUP: $23.01SMA50: $25.74SMA200: $16.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XNCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XNCR Butterfly Map → + Track XNCR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +13.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XNCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XNCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XNCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XNCR)

Health Care Rank #539 of 1016 ⚔️ PVLA vs XNCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XNCR vs. PVLA, IMNM, MRVI, VERA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xencor Inc. (XNCR) ranks #539 by composite RQD confidence (43/100, grade D-) and #250 by equity capitalization ($2.17B). Within this direct 5-issuer industry benchmark cohort, XNCR leads on earnings valuation at N/A trailing P/E, while XNCR leads on capital efficiency and profitability with -21.3% ROIC and — gross margin. PVLA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with XNCR at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XNCR ACTIVE Xencor Inc.	D-	43/100	—	—	-21.3%	-2.60%	$2.17B	Benchmark Subject
PVLA Palvella Therapeutics Inc.	D	46/100	—	—	-27.9%	+2.79%	$2.18B	/pvla-vs-xncr →
IMNM Immunome Inc.	D-	38/100	—	—	-35.0%	-2.50%	$2.16B	/imnm-vs-xncr →
MRVI Maravai LifeSciences Holdings Inc. (Class A)	D-	36/100	—	18.3%	-35.0%	-0.47%	$2.20B	/mrvi-vs-xncr →
VERA Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	/vera-vs-xncr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326732

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xencor Inc. (XNCR) reported GAAP revenue of $125.6M (+13.7% vs. FY2024 revenue of $110.5M , and -28.1% cumulative change since FY2023) , GAAP net income of -$91.9M, operating cash flow of -$135.1M, and free cash flow of -$138.3M (+33.6% YoY). On the balance sheet, XNCR closed FY2025 with $875.5M in total assets against $76.5M in total debt (Altman Z-Score: 4.32, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$125.6M	-$91.9M	-$135.1M	-$138.3M	$875.5M	$76.5M
FY2024 (FY)	2024-12-31	$110.5M	-$232.6M	-$202.2M	-$208.3M	$951.9M	$115.2M
FY2023 (FY)	2023-12-31	$174.6M	-$133.1M	-$77.9M	-$77.9M	—	—

3. XNCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XNCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Xencor Inc. (NASDAQ: XNCR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $29.21 (-2.60% 1D, market cap $2.17B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XNCR ranks #539 in composite RQD confidence.

How does XNCR compare to PVLA and IMNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XNCR carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.3%. By comparison, PVLA (Palvella Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -27.9%, cap $2.18B) and IMNM (Immunome Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.16B). Among the 5-stock peer group, XNCR leads on earnings multiple (N/A) while XNCR leads on capital efficiency (-21.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XNCR?

Per XNCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326732), Xencor Inc. generated $125.6M in revenue (+13.7% YoY), -$91.9M in net income, and -$138.3M in free cash flow against $875.5M in total assets and $76.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XNCR trading relative to its 50-day, 200-day, and 52-week technical levels?

XNCR last traded at $29.21 (-2.60% on volume of 931,250 shares), positioning the stock +13.48% above its 50-day simple moving average ($25.74) and +72.23% above its 200-day simple moving average ($16.96). Across its 52-week range of $10.38 to $33.60, XNCR sits at the 81.1% percentile with a 14-day RSI of 68.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.56 to $32.86).